195 related articles for article (PubMed ID: 26940688)
1. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
2. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Goldstein LJ; O'Neill A; Sparano JA; Perez EA; Shulman LN; Martino S; Davidson NE
J Clin Oncol; 2008 Sep; 26(25):4092-9. PubMed ID: 18678836
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Vici P; Brandi M; Giotta F; Foggi P; Schittulli F; Di Lauro L; Gebbia N; Massidda B; Filippelli G; Giannarelli D; Di Benedetto A; Mottolese M; Colucci G; Lopez M
Ann Oncol; 2012 May; 23(5):1121-1129. PubMed ID: 21965475
[TBL] [Abstract][Full Text] [Related]
4. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
Mavroudis D; Saloustros E; Boukovinas I; Papakotoulas P; Kakolyris S; Ziras N; Christophylakis C; Kentepozidis N; Fountzilas G; Rigas G; Varthalitis I; Kalbakis K; Agelaki S; Hatzidaki D; Georgoulias V
Br J Cancer; 2017 Jul; 117(2):164-170. PubMed ID: 28641315
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran.
Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A
Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847
[TBL] [Abstract][Full Text] [Related]
6. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
Bandos H; Melnikow J; Rivera DR; Swain SM; Sturtz K; Fehrenbacher L; Wade JL; Brufsky AM; Julian TB; Margolese RG; McCarron EC; Ganz PA
J Natl Cancer Inst; 2018 Feb; 110(2):. PubMed ID: 28954297
[TBL] [Abstract][Full Text] [Related]
7. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
Morris PG; Dickler M; McArthur HL; Traina T; Sugarman S; Lin N; Moy B; Come S; Godfrey L; Nulsen B; Chen C; Steingart R; Rugo H; Norton L; Winer E; Hudis CA; Dang CT
J Clin Oncol; 2009 Dec; 27(36):6117-23. PubMed ID: 19901120
[TBL] [Abstract][Full Text] [Related]
8. Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
Reeder-Hayes KE; Meyer AM; Hinton SP; Meng K; Carey LA; Dusetzina SB
J Clin Oncol; 2017 Oct; 35(29):3298-3305. PubMed ID: 28727517
[TBL] [Abstract][Full Text] [Related]
9. Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.
Orlando L; Maiello E; Orditura M; Diana A; Antoniol G; Morritti MG; Aieta M; Ciccarese M; Pisconti S; Bordonaro R; Russo A; Febbraro A; Schiavone P; Quaranta A; Caliolo C; Loparco D; Cinefra M; Colucci G; Cinieri S;
Breast; 2024 Jun; 75():103725. PubMed ID: 38615483
[TBL] [Abstract][Full Text] [Related]
10. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
[TBL] [Abstract][Full Text] [Related]
11. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).
Lara JF; Thor AD; Dressler LG; Broadwater G; Bleiweiss IJ; Edgerton S; Cowan D; Goldstein LJ; Martino S; Ingle JN; Henderson IC; Norton L; Winer EP; Hudis CA; Ellis MJ; Berry DA; Hayes DF;
Clin Cancer Res; 2011 Aug; 17(15):5170-8. PubMed ID: 21693655
[TBL] [Abstract][Full Text] [Related]
12. Quantifying Chemotherapy Delivery in Older and Younger Women With Early-Stage Breast Cancer Using Longitudinal Cumulative Dose.
Pak J; Nyrop KA; Muss HB; Forster MK; Lund JL
Oncologist; 2024 Apr; 29(4):311-315. PubMed ID: 38330406
[TBL] [Abstract][Full Text] [Related]
13. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
Werida RH; Elshafiey RA; Ghoneim A; Elzawawy S; Mostafa TM
Support Care Cancer; 2022 Sep; 30(9):7281-7292. PubMed ID: 35596774
[TBL] [Abstract][Full Text] [Related]
14. Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in
de Maar JS; Suelmann BBM; Braat MNGJA; van Diest PJ; Vaessen HHB; Witkamp AJ; Linn SC; Moonen CTW; van der Wall E; Deckers R
BMJ Open; 2020 Nov; 10(11):e040162. PubMed ID: 33243800
[TBL] [Abstract][Full Text] [Related]
15. A prospective study to evaluate the efficacy and safety of vitamin E and levocarnitine prophylaxis against doxorubicin-induced cardiotoxicity in adult breast cancer patients.
Moustafa I; Connolly C; Anis M; Mustafa H; Oosthuizen F; Viljoen M
J Oncol Pharm Pract; 2024 Mar; 30(2):354-366. PubMed ID: 37157803
[TBL] [Abstract][Full Text] [Related]
16. Evaluate the in vitro effect of anthracycline and alkylating cytophosphane chemotherapeutics on dopaminergic neurons.
Desai D; Majrashi M; Pathak S; Almaghrabi M; Liu K; Pondugula SR; Tiwari AK; Babu RJ; Deruiter J; Dhanasekaran M
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2074. PubMed ID: 38627904
[TBL] [Abstract][Full Text] [Related]
17. Determination of drug-drug interaction in breast cancer patients receiving doxorubicin and cyclophosphamide regimen.
Mahfouz M; Alkhalid ZN; Birand N
J Oncol Pharm Pract; 2024 Jul; 30(5):830-843. PubMed ID: 37489038
[TBL] [Abstract][Full Text] [Related]
18. Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer.
Poorvu PD; Hu J; Zheng Y; Gelber SI; Ruddy KJ; Tamimi RM; Peppercorn JM; Schapira L; Borges VF; Come SE; Warner E; Lambertini M; Rosenberg SM; Partridge AH
NPJ Breast Cancer; 2021 Jul; 7(1):99. PubMed ID: 34315890
[TBL] [Abstract][Full Text] [Related]
19. Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience.
El Rassy E; Ghosn M; Farhat F; Bakouny Z; Assi T; Chahine G; Nasr F; Haddad FG; El Karak F; Kattan J
Breast Care (Basel); 2018 Apr; 13(2):121-125. PubMed ID: 29887789
[TBL] [Abstract][Full Text] [Related]
20. Difference in Estimation of Side Effects of Chemotherapy between Physicians and Patients with Early-Stage Breast Cancer: The Use of Patient Reported Outcomes (PROs) in the Evaluation of Toxicity in Everyday Clinical Practice.
Pavlović Mavić M; Šeparović R; Tečić Vuger A; Vazdar L
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
